A Deep Dive on Cell Therapy: Applying Lessons Learned from First-Generation Cell Therapies

For a long time, the products developed and marketed by the pharmaceutical industry consisted of small molecule drugs and natural products such as insulin. A couple of decades ago, biologics revolutionized the drug industry with the introduction of agents such as recombinant proteins and monoclonal antibodies. Today, a third arm is emerging in the form of “cells as drugs” or more concisely, cell therapy. This panel will describe some of the technological, regulatory and commercial differences implied by cell therapy adoption and some development directions that are expected to enable the greatest benefit.